Ligne de temps

Rita Azevedo
Ingénieur(e) de Recherche
09 avr. 2022
publication
Mass Spectrometry for Neurobiomarker Discovery: The Relevance of Post-Translational Modifications.
Lire plus01 janv. 2022
publication
Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.
Lire plus09 juin 2021
publication
Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer.
Lire plus07 févr. 2021
publication
Target Score-A Proteomics Data Selection Tool Applied to Esophageal Cancer Identifies GLUT1-Sialyl Tn Glycoforms as Biomarkers of Cancer Aggressiveness.
Lire plus02 avr. 2020
publication
Nucleolin-Sle A Glycoforms as E-Selectin Ligands and Potentially Targetable Biomarkers at the Cell Surface of Gastric Cancer Cells.
Lire plus25 mars 2019
publication
Exploring sialyl-Tn expression in microfluidic-isolated circulating tumour cells: A novel biomarker and an analytical tool for precision oncology applications.
Lire plus01 janv. 2019
publication
Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks.
Lire plus01 juil. 2018
publication
Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer.
Lire plus01 mai 2018
publication
Circulating tumor cells in bladder cancer: Emerging technologies and clinical implications foreseeing precision oncology.
Lire plus16 janv. 2018
01 janv. 2018
publication
CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications.
Lire plus01 déc. 2017
publication
Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases.
Lire plus31 oct. 2017
publication
Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?
Lire plus01 août 2017
publication
Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours.
Lire plus01 oct. 2016
publication
Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome.
Lire plus27 sept. 2016
publication
Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension.
Lire plus01 oct. 2015
publication
Smartphone application for rheumatoid arthritis self-management: cross-sectional study revealed the usefulness, willingness to use and patients’ needs.
Lire plus28 sept. 2015
publication
Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review.
Lire plus16 juin 2015
publication
Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?
Lire plus01 mars 2015
publication
Future perspectives of Smartphone applications for rheumatic diseases self-management.
Lire plus01 nov. 2014
publication
SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.
Lire plus01 avr. 2014
publication
SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients.
Lire plus01 janv. 2014
publication
Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers.
Lire plus01 janv. 2014
publication
Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients.
Lire plus01 janv. 2014
publication
Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms.
Lire plus01 août 2013
publication